Conference Coverage

Diabetes from checkpoint inhibitors probably means lifelong insulin


 

REPORTING FROM ENDO 2018


The median age at diabetes presentation was 61 years and ranged from 32 to 82 years. The majority of patients were men, which reflects MD Anderson demographics, not a predisposing risk factor, Dr. Iyer said.

Melanoma was the most common cancer, followed by renal cell and prostate; patients had stage 2-4 disease. About half the subjects were on single agent anti-PD-1 treatment, about a third on anti-PD-1 combination treatment, and the rest on anti-PD-L1 combination therapy. C-peptide levels were below 0.9 ng/mL at diabetes diagnosis in most of the patients. Eleven of the 20 tested (55%) were positive for the pancreatic islet cell antibody GAD65.

The investigators had no disclosures. A funding source was not reported.

SOURCE: Iyer PC et al. Abstract OR05-5.

Pages

Recommended Reading

VIDEO: Pioglitazone benefited NASH patients with and without T2DM
MDedge Endocrinology
FDA approves highest capacity insulin pen
MDedge Endocrinology
Robocalls increase diabetic retinopathy screenings in low-income patients
MDedge Endocrinology
MDedge Daily News: Why low-calorie sucralose may fuel weight gain
MDedge Endocrinology
MDedge Daily News: How European data privacy rules may cost you
MDedge Endocrinology
Metformin reduces preterm births, late miscarriages in PCOS
MDedge Endocrinology
Hope and hype: Inside the push for wearable diabetes technology
MDedge Endocrinology
Sensitivity of vibration-based neuropathy detectors varies widely
MDedge Endocrinology
Being overweight as a child increases the risk of developing diabetes
MDedge Endocrinology
Clearer picture emerging of renal impact of SGLT2s
MDedge Endocrinology